FDA-approved1,2Evidence: Smaller human trialsMetabolic and weight

Setmelanotide1

Also called Imcivree1

Key takeaway

Setmelanotide is a lab-made peptide that activates the MC4 receptor, part of a brain pathway that regulates hunger and energy use, and is the active ingredient in Imcivree from Rhythm.1,2 It is FDA-approved only for specific rare causes of obesity: acquired hypothalamic obesity from age 4, and Bardet-Biedl syndrome or genetically confirmed POMC, PCSK1 or LEPR deficiency from age 2. The label states that it is not indicated for general obesity.1 Its evidence comes from small trials, including a randomized, placebo-controlled trial of 142 people with acquired hypothalamic obesity.1

Setmelanotide at a glance

What it isAn MC4 receptor agonist. The label states that it has about 20-fold less activity at the MC3 and MC1 receptors.1
FDA statusFDA-approved. Drugs@FDA lists Imcivree with an original approval date of November 25, 2020, and the label limits it to specific rare causes of obesity. The cited label has no boxed warning.1,2
Human evidenceA randomized, placebo-controlled trial in 142 people with acquired hypothalamic obesity, and smaller open-label trials in genetic forms of obesity, described in the label.1
Evidence strengthSmaller controlled human trials. The cited sources include randomized or otherwise controlled human trials that are fully reported in a journal article or in posted registry results, but none meets the large-trial rule. How this label is assigned

What is setmelanotide?

Setmelanotide is a lab-made peptide that the label describes as an MC4 receptor agonist.1

In the United States it is the active ingredient of Imcivree, from Rhythm, according to Drugs@FDA.2

How does setmelanotide work?

The label states that MC4 receptors in the brain are involved in regulating hunger, fullness and energy use, and that, based on nonclinical evidence, setmelanotide may restore activity in this pathway in conditions where it is not activated enough.1

The label also states that setmelanotide acts weakly on the MC1 receptor on pigment cells, which can darken the skin.1

What do human studies show?

In a randomized, double-blind, placebo-controlled trial in 142 people aged 4 and older with acquired hypothalamic obesity, body-mass index fell by an average of 18.40 percentage points more with setmelanotide than with placebo after 52 weeks, according to the label.1

In 44 people with Bardet-Biedl syndrome, the average change in body-mass index after 52 weeks of treatment was −7.9%, and 38.7% had a reduction of at least 10%, according to the label. That result comes from the open-label part of the trial.1

The label also describes one-year open-label trials in 21 people with POMC, PCSK1 or LEPR deficiency and a trial in 12 children aged 2 to under 6. These trials had no parallel placebo group for their main results.1

What the evidence base contains

  • Controlled human trial Trial 1 (NCT05774756): a randomized, double-blind, placebo-controlled trial of 56 to 60 weeks in 142 people aged 4 and older with acquired hypothalamic obesity.1
  • Controlled human trial Trial 2 (NCT03746522): 44 people with Bardet-Biedl syndrome, with a 14-week randomized, placebo-controlled period followed by 52 weeks of open-label treatment.1
  • Small, short, or incompletely reported human study Two one-year open-label trials in 21 people with POMC, PCSK1 or LEPR deficiency (NCT02896192 and NCT03287960), and a 52-week open-label trial in 12 children aged 2 to under 6.1

Evidence-strength label: Smaller controlled human trials. How this label is assigned

Is setmelanotide FDA-approved?

Yes. Drugs@FDA lists Imcivree, application NDA213793, with an original approval date of November 25, 2020.2

The Imcivree label cited here (DailyMed SPL version 14, published April 2, 2026) states that it is indicated to reduce excess body weight and maintain the reduction long term in people aged 4 and older with acquired hypothalamic obesity, and in people aged 2 and older with Bardet-Biedl syndrome or POMC, PCSK1 or LEPR deficiency confirmed by genetic testing.1

The label states that it is not indicated for obesity linked to benign gene variants or for other types of obesity, including general (polygenic) obesity, where it would not be expected to work.1

The label has no boxed warning. It states that setmelanotide is contraindicated in people with prior serious allergic reactions to it, and its warnings cover sexual-arousal effects, depression and suicidal thoughts, allergic reactions, skin darkening and new or darker moles, and, in acquired hypothalamic obesity, acute adrenal insufficiency and sodium imbalance in people with central diabetes insipidus.1

Timeline

  1. FDA approves Imcivree, according to Drugs@FDA.2
  2. DailyMed publishes the Imcivree label version cited on this page.1

What is still unknown?

Its effects in general obesity, for which the label says it is not indicated and would not be expected to work.1

How durable the results are in the genetic obesity trials, which were small and mostly open-label.1

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Go deeper

Records, reviews and history

Everything PeptideScanner has collected for Setmelanotide: reviews, official-source readings, registry and literature records, and every change to this profile.

What the trial and literature lists cover. The trials and papers listed for Setmelanotide are the records PeptideScanner has selected and published, not every registration or paper about Setmelanotide. A daily check adds newly updated registrations and newly indexed papers that pass the publication checks. How records are selected.

Status brief and reviewed-evidence summary

Evidence summary

What the cited records show

What is its status in the cited records?

FDA-approved as Imcivree for specific rare causes of obesity. A randomized, placebo-controlled trial in 142 people with acquired hypothalamic obesity and smaller open-label trials in genetic forms of obesity are described in the label. The label states that it is not indicated for general obesity.↗↗

Status sources checked through July 22, 2026. See status sources and coverage →

What do the reviewed human studies say?

Human evidence reviewed September 20, 2026 · Review version 2.

Review source snapshots checked September 20, 2026 · Integrity checked September 20, 2026.

Publisher notices are registered for this reviewed source set. Inspect the notices and their scope →

A bounded review of sponsor-funded Phase 3 studies in rare genetic obesity syndromes: two small single-arm trials with withdrawal periods and one randomized trial followed by an open-label period.↗↗

What the reviewed sources report

The reviewed studies reported substantial weight reductions in some participants with specific genetic diagnoses. The cohorts were very small, and the Bardet-Biedl and Alström trial reported inconclusive results for the Alström subgroup.↗↗

What remains unresolved?

  • How durable are benefits and harms across each genetic subgroup, and which baseline features predict response in these exceptionally small populations?↗↗

Read study designs, results, limitations, and sources →

What does the U.S. product label say?

Imcivree · Read September 15, 2026 · Preserved label summary 1

Which population and use does the label cover?

The label covers acquired hypothalamic obesity from age four, and Bardet-Biedl syndrome or specified genetically confirmed POMC, PCSK1 or LEPR deficiency from age two. It explicitly excludes general polygenic obesity and specified benign genetic variants. Label: 1 ↗

Which safety limits matter?

Warnings address sexual-arousal effects, depression or suicidal ideation, serious hypersensitivity, pigmentary changes and new or darkened nevi. For acquired hypothalamic obesity, the label adds acute adrenal insufficiency and, with central diabetes insipidus, sodium imbalance. Label: 4, 5 ↗

Label edition and source pins

U.S. product labeling hosted by the National Library of Medicine. This account concerns this product and label edition; other formulations and jurisdictions require their own records.

IMCIVREE (setmelanotide) solution · SPL version 14 · published 2026-04-02

Label ZIP SHA-256: 3a9024abc434e828923d30e4f860e834f3887ceece2a7a47cdc1c8828105e6f1. Extracted XML SHA-256: b144f343fa74b6d436776a8f7fcb548db348e1c7ffcc8e567930b96cd3b1b812.

Open versioned label context data →

Reviews summarize selected studies; their scope and limitations are shown above.

Read the full Human Evidence Review

Supervised synthesis

What do selected human studies report about Setmelanotide?

Manually reviewed September 20, 2026 · version 2

Browse all Human Evidence Reviews · Open preserved synthesis version 2 →

A bounded review of sponsor-funded Phase 3 studies in rare genetic obesity syndromes: two small single-arm trials with withdrawal periods and one randomized trial followed by an open-label period.12

Bottom line from this bounded source set

The reviewed studies reported substantial weight reductions in some participants with specific genetic diagnoses. The cohorts were very small, and the Bardet-Biedl and Alström trial reported inconclusive results for the Alström subgroup.12

Reviewed study record

POMC-deficiency obesity trial

Design

A sponsor-funded, single-arm, open-label phase 3 trial included a blinded placebo-withdrawal sequence for participants who first met a weight-loss threshold.1

Population

Ten participants aged at least six years with POMC-deficiency obesity were included in the full analysis and safety sets.1

Outcomes reported

Eight of ten participants achieved at least 10% weight loss at approximately one year. The hunger-score analysis involved a selected subset of seven participants aged at least 12 years who had first met the weight-loss threshold.1

Limitations

The primary one-year endpoint lacked a parallel control group. The small cohort and response-selected withdrawal and hunger analyses limit interpretation and do not establish outcomes in other causes of obesity.1

Reviewed study record

LEPR-deficiency obesity trial

Design

A sponsor-funded, single-arm, open-label phase 3 trial included a blinded placebo-withdrawal sequence for participants who first met a weight-loss threshold.1

Population

Eleven participants aged at least six years with LEPR-deficiency obesity were included in the full analysis and safety sets.1

Outcomes reported

Five of eleven participants achieved at least 10% weight loss at approximately one year. The hunger-score analysis involved a selected subset of seven participants aged at least 12 years who had first met the weight-loss threshold.1

Limitations

The primary one-year endpoint lacked a parallel control group. The small cohort and response-selected withdrawal and hunger analyses limit interpretation and do not establish outcomes in other causes of obesity.1

Reviewed study record

Bardet-Biedl and Alström syndrome trial

Design

A sponsor-funded Phase 3 trial began with a 14-week double-blind randomized placebo-controlled period and continued with a 52-week open-label period.2

Population

The trial randomized 38 participants aged six years or older with obesity and Bardet-Biedl syndrome or Alström syndrome.2

Outcomes reported

After 52 weeks of treatment, 32.3% of participants aged at least 12 years with Bardet-Biedl syndrome reached at least 10% weight reduction; results were reported as inconclusive for Alström syndrome.2

Limitations

The primary endpoint followed the open-label period, the syndrome-specific groups were small, and the reported result should not be generalized beyond the defined genetic populations.2

Reviewed source set

  1. PubMed · 33137293Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials ↗PubMed PMID 33137293 · EFetch XML reviewed 2026-09-20 · payload SHA-256 04d73cd4656ccf5ac7e3429077a068278bbe91f299a004c2a5a3b9cdad044c9c
    No registered Crossref update in the reviewed snapshotChecked September 20, 2026 for DOI 10.1016/s2213-8587(20)30364-8. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
  2. PubMed · 36356613Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, in patients with Bardet-Biedl syndrome and Alström syndrome: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial with an open-label period ↗PubMed PMID 36356613 · EFetch XML reviewed 2026-08-19 · payload SHA-256 7b5354b639322709facbb381c2df8b0849df463946623456b329b9ce8d42032e
    Publication update registered by CrossrefErratum ↗ · publisher metadata · February 1, 2023. Crossref metadata identifies the notice but does not by itself explain what wording changed.
Official-source readings

Inside the official reviews

Reviewed 2026-09-19 · Preserved version 1

Small, genetically defined study populations

The 2020 FDA review reports at least 10% weight loss at one year in 8 of 10 participants with POMC/PCSK1 deficiency and 5 of 11 with LEPR deficiency. These small groups and their wide confidence intervals limit precision; the findings are not estimates for general obesity. FDA PDF pp. 20 ↗

More findings, study links and document coverage

Withdrawal evidence is not a year-long placebo comparison

The studies were mainly open-label. An initial-response requirement selected participants for a short blinded withdrawal period. FDA’s full-analysis estimates also included early nonresponders, avoiding the larger effects obtained from a responder-enriched subset. FDA PDF pp. 4, 20, 21 ↗

Hunger findings were less secure than weight findings

FDA considered the hunger results suggestive but insufficient to establish substantial evidence of an effect. The review cites subjective assessment, open-label expectations, missing data and limitations of the measurement instruments. FDA PDF pp. 5 ↗

Keep the original indication separate from later expansions

This reading covers the original POMC/PCSK1 and LEPR submission, not every subsequently approved population. Its small safety database also limits conclusions about uncommon or long-term harms. FDA PDF pp. 2, 5 ↗

Read the separate U.S. label account → Label version and indication scope are preserved there; these agency reviews describe their own dated evidence.

Document coverage

Selected sections read in 1 of 25 inventoried documents; 24 not yet reviewed. Reading selected sections does not establish complete appraisal of a document.

Selected English EMA PDFs from the retained September 15, 2026 title-matched document feed, plus independently retrieved FDA approval-package documents where listed. Candidate entries are not verified product/application matches. This is a bounded inventory, not a complete FDA, national or worldwide source search. EMA inventory source ↗

Inspect documents, application identities and source pins

Page references use one-based PDF file pages, which can differ from printed page numbers. Candidate feed associations are not verified application identities.

Remaining work

  • Appraise the later Bardet–Biedl syndrome and pediatric regulatory extensions separately.
  • Resolve the linked literature correction before treating the affected report as fully appraised.

Open versioned document coverage and study pins →

European medicine records · 1 products or applications

EMA medicine metadata checked 2026-09-15. These are product-specific centralized records; national European authorizations and full product-information assessments require separate coverage.

Application withdrawal and refusal are distinct from marketing authorization. A withdrawal status alone does not establish why it occurred. These metadata entries do not substitute for indication, population or safety details in the relevant product information.

Open versioned records and source-feed pins →

Research coverage and study families

Search and screening record checked 2026-09-15. Counts describe records, not independent trials. Full-text appraisal is separate from an abstract review.

Open machine-readable coverage and record decisions →

PubMed search

Catalog-name and calibrated alias discovery for human evidence review. Complete query retrieval is separate from clinical eligibility, study-family linkage and appraisal.

219 retrieved · 2 included · 0 excluded · 217 awaiting a decision · 0 full-text appraisals

Search terms, record decisions and remaining work

"Setmelanotide"[Title/Abstract] OR "RM-493"[Title/Abstract] OR "Imcivree"[Title/Abstract]

Source retrievals and payload pins
  • Open the source endpoint ↗

    Retrieved 2026-09-15T11:09:41.823675+00:00 · HTTP 200 · SHA-256 d6163eee371c6b214f57e1788ed49e9c9112dbcde46db1fd0329518010a02a0d.

  • Retrieved IDs completely represent this query response, not all relevant literature. Additional aliases, references and non-PubMed sources require separate searches.
  • Unscreened records may include animal or cell experiments, reviews, secondary analyses, mixtures, protocols and unrelated name matches.
  • Study-family mappings use available declared registry IDs; unresolved mappings do not create independent trial counts. Full-text, corrections and registry comparison remain separate work.
  • Linked correction notices require comparison with the selected reports: PMID36702567 for PMID36356613. Their presence does not establish what changed.

Showing 25 of 219 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

  1. PubMed 36356613 — include: Selected published human report; abstract reviewed. Full-text and study-family appraisal remain separate. Study families: NCT03746522.
    Bibliographic record recheck · 2026-09-15

    The selected PubMed XML payload matches the previous reviewed snapshot. This is a metadata recheck, not a new appraisal or a finding that no corrections exist. Open PubMed record ↗

    SHA-256 7b5354b639322709facbb381c2df8b0849df463946623456b329b9ce8d42032e.

  2. PubMed 33137293 — include: Selected published human report; abstract reviewed. Full-text and study-family appraisal remain separate. Study families: NCT02896192; NCT03287960.
    Bibliographic record recheck · 2026-09-15

    The selected PubMed XML payload matches the previous reviewed snapshot. This is a metadata recheck, not a new appraisal or a finding that no corrections exist. Open PubMed record ↗

    SHA-256 04d73cd4656ccf5ac7e3429077a068278bbe91f299a004c2a5a3b9cdad044c9c.

  3. PubMed 42737637 — not screened: Name-query match awaiting clinical eligibility screening.
  4. PubMed 42697206 — not screened: Name-query match awaiting clinical eligibility screening.
  5. PubMed 42626294 — not screened: Name-query match awaiting clinical eligibility screening.
  6. PubMed 42611594 — not screened: Name-query match awaiting clinical eligibility screening.
  7. PubMed 42672527 — not screened: Name-query match awaiting clinical eligibility screening.
  8. PubMed 42592034 — not screened: Name-query match awaiting clinical eligibility screening.
  9. PubMed 42538728 — not screened: Name-query match awaiting clinical eligibility screening.
  10. PubMed 42528856 — not screened: Name-query match awaiting clinical eligibility screening.
  11. PubMed 42499770 — not screened: Name-query match awaiting clinical eligibility screening.
  12. PubMed 42498078 — not screened: Name-query match awaiting clinical eligibility screening.
  13. PubMed 42496807 — not screened: Name-query match awaiting clinical eligibility screening.
  14. PubMed 42479131 — not screened: Name-query match awaiting clinical eligibility screening.
  15. PubMed 42466340 — not screened: Name-query match awaiting clinical eligibility screening.
  16. PubMed 42418774 — not screened: Name-query match awaiting clinical eligibility screening.
  17. PubMed 42340853 — not screened: Name-query match awaiting clinical eligibility screening.
  18. PubMed 42339090 — not screened: Name-query match awaiting clinical eligibility screening.
  19. PubMed 42329358 — not screened: Name-query match awaiting clinical eligibility screening.
  20. PubMed 42325616 — not screened: Name-query match awaiting clinical eligibility screening.
  21. PubMed 42475468 — not screened: Name-query match awaiting clinical eligibility screening.
  22. PubMed 42259622 — not screened: Name-query match awaiting clinical eligibility screening.
  23. PubMed 42209772 — not screened: Name-query match awaiting clinical eligibility screening.
  24. PubMed 42205046 — not screened: Name-query match awaiting clinical eligibility screening.
  25. PubMed 42114845 — not screened: Name-query match awaiting clinical eligibility screening.

FDA search

Active-ingredient name query in openFDA Drugs@FDA. Returned application identities include salt forms and combination products; exact indications, approval conditions, supplements and marketing status require document-level review.

1 retrieved · 1 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals

Search terms, record decisions and remaining work

products.active_ingredients.name:"SETMELANOTIDE"

Source retrievals and payload pins
  • Open the source endpoint ↗

    Retrieved 2026-09-15T11:10:27.731150+00:00 · HTTP 200 · SHA-256 fd53e36b37518d650a6b24297a35acfa8a100f90579d1d2cccf87d2a51af3fb8.

  • Zero results describe this query response only, not absence of FDA approval or worldwide nonapproval.
  • This endpoint does not inventory every label, advisory proceeding, safety communication or regulatory document. Application inclusion does not establish current marketing or approval of every use.

Showing 1 of 1 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

  1. FDA NDA213793 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: SETMELANOTIDE ACETATE.

EMA search

Local matching in the pinned EMA medicines feed; document matches also use identified EMA product numbers. This is not every national European record.

1 retrieved · 1 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals

Search terms, record decisions and remaining work

Case-insensitive word-boundary identity terms: ["Setmelanotide", "Imcivree"]

Source retrievals and payload pins
  • Open the source endpoint ↗

    Retrieved 2026-09-15T08:34:22.905972+00:00 · HTTP 200 · SHA-256 a947c2b8a56ac2b92ec96156843f262f5e516f83b375d6791d67a8f6dc695729.

  • Document appraisal and national European sources remain open.
  • Zero matches apply only to these feed fields and terms; orphan designation is not approval.

Showing 1 of 1 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

  1. EMA EMEA/H/C/005089 — include: EMA feed product Imcivree; reported status: Authorised. Exact indication and decision documents remain unappraised.

EMA search

Local matching in the pinned EMA documents feed; document matches also use identified EMA product numbers. This is not every national European record.

32 retrieved · 14 included · 0 excluded · 18 awaiting a decision · 0 full-text appraisals

Search terms, record decisions and remaining work

Case-insensitive word-boundary identity terms: ["Setmelanotide", "Imcivree"]

Source retrievals and payload pins
  • Open the source endpoint ↗

    Retrieved 2026-09-15T08:34:29.167460+00:00 · HTTP 200 · SHA-256 c0c68d7d77783e0355cbc75bdd04772e9acc163236fc68abcd794477c4c3d439.

  • Document appraisal and national European sources remain open.
  • Zero matches apply only to these feed fields and terms; orphan designation is not approval.

Showing 25 of 32 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

  1. EMA 52006 — include: Document linked by EMA product number; content unappraised. Imcivree : EPAR - All authorised presentations
  2. EMA 52007 — include: Document linked by EMA product number; content unappraised. Imcivree : EPAR - Public assessment report
  3. EMA 52010 — include: Document linked by EMA product number; content unappraised. Imcivree : EPAR - Orphan maintenance assessment report (initial authorisation)
  4. EMA 56230 — include: Document linked by EMA product number; content unappraised. Imcivree-H-C-005089-II-0002-G : EPAR - Assessment report - Variation
  5. EMA 56231 — include: Document linked by EMA product number; content unappraised. Imcivree : EPAR - Orphan maintenance assessment report (post authorisation)
  6. EMA 64908 — include: Document linked by EMA product number; content unappraised. Imcivree-H-C-005089-P46-009 : EPAR - Assessment report
  7. EMA 52988 — include: Document linked by EMA product number; content unappraised. Imcivree : EPAR - Procedural steps taken and scientific information after authorisation (archive)
  8. EMA 52008 — include: Document linked by EMA product number; content unappraised. Imcivree : EPAR - Risk management plan
  9. EMA 73856 — include: Document linked by EMA product number; content unappraised. Imcivree-VR-0000288021 : EPAR - Assessment report - Variation
  10. EMA 73857 — include: Document linked by EMA product number; content unappraised. Imcivree : Orphan maintenance assessment report (post authorisation)
  11. EMA 52004 — include: Document linked by EMA product number; content unappraised. Imcivree : EPAR - Medicine overview
  12. EMA 72292 — include: Document linked by EMA product number; content unappraised. Imcivree : EPAR - Procedural steps taken and scientific information after authorisation
  13. EMA 52005 — include: Document linked by EMA product number; content unappraised. Imcivree : EPAR - Product information
  14. EMA 65061 — include: Document linked by EMA product number; content unappraised. Imcivree-H-C-005089-II-0018 : EPAR - Assessment report - Variation
  15. EMA 14179 — not screened: Title-name match awaiting identity and document review. EU/3/16/1703: Public summary of opinion on orphan designation: Setmelanotide for the treatment of pro-opiomelanocortin deficiency
  16. EMA 31788 — not screened: Title-name match awaiting identity and document review. EU/3/16/1688: Public summary of opinion on orphan designation: Setmelanotide for the treatment of Prader-Willi syndrome
  17. EMA 43893 — not screened: Title-name match awaiting identity and document review. EU/3/18/2101: Public summary of opinion on orphan designation: Setmelanotide for the treatment of leptin receptor deficiency
  18. EMA 46421 — not screened: Title-name match awaiting identity and document review. EU/3/05/269: Public summary of positive opinion for orphan designation of setmelanotide for the treatment of Bardet Biedl syndrome
  19. EMA 47738 — not screened: Title-name match awaiting identity and document review. EU/3/19/2245: Public summary of opinion on orphan designation for setmelanotide for the treatment of Alström syndrome
  20. EMA 51223 — not screened: Title-name match awaiting identity and document review. CHMP summary of positive opinion for Imcivree
  21. EMA 55624 — not screened: Title-name match awaiting identity and document review. Questions and answers on the withdrawal of application to change the marketing authorisation for Imcivree (setmelanotide)
  22. EMA 55626 — not screened: Title-name match awaiting identity and document review. Withdrawal letter: Imcivree
  23. EMA 55632 — not screened: Title-name match awaiting identity and document review. CHMP post-authorisation summary of positive opinion for Imcivree (II-02-G)
  24. EMA 56223 — not screened: Title-name match awaiting identity and document review. Withdrawal assessment report for Imcivree
  25. EMA 63789 — not screened: Title-name match awaiting identity and document review. CHMP post-authorisation summary of positive opinion for Imcivree (II-18)

EMA search

Local matching in the pinned EMA orphans feed; document matches also use identified EMA product numbers. This is not every national European record.

6 retrieved · 6 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals

Search terms, record decisions and remaining work

Case-insensitive word-boundary identity terms: ["Setmelanotide", "Imcivree"]

Source retrievals and payload pins
  • Open the source endpoint ↗

    Retrieved 2026-09-15T08:34:31.262344+00:00 · HTTP 200 · SHA-256 7448bf4e77e3345b3f3fbb7062c335d2302d8ea458a246bbe8256ce48aad2806.

  • Document appraisal and national European sources remain open.
  • Zero matches apply only to these feed fields and terms; orphan designation is not approval.

Showing 6 of 6 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

  1. EMA EU/3/23/2833 — include: EMA orphan feed identifies setmelanotide; designation status: Positive. Orphan designation is not marketing authorization.
  2. EMA EU/3/19/2192 — include: EMA orphan feed identifies setmelanotide; designation status: Positive. Orphan designation is not marketing authorization.
  3. EMA EU/3/19/2245 — include: EMA orphan feed identifies setmelanotide; designation status: Positive. Orphan designation is not marketing authorization.
  4. EMA EU/3/18/2101 — include: EMA orphan feed identifies setmelanotide; designation status: Positive. Orphan designation is not marketing authorization.
  5. EMA EU/3/16/1703 — include: EMA orphan feed identifies setmelanotide; designation status: Positive. Orphan designation is not marketing authorization.
  6. EMA EU/3/16/1688 — include: EMA orphan feed identifies setmelanotide; designation status: Positive. Orphan designation is not marketing authorization.

ClinicalTrials.gov search

ClinicalTrials.gov name/alias discovery, including cited product names. Matches may concern combinations, background references or different formulations; identity and outcomes need screening.

30 retrieved · 0 included · 0 excluded · 30 awaiting a decision · 0 full-text appraisals

Search terms, record decisions and remaining work

"Setmelanotide" OR "Imcivree" OR "RM-493"

Source retrievals and payload pins
  • Open the source endpoint ↗

    Retrieved 2026-09-15T11:27:05.383211+00:00 · HTTP 200 · SHA-256 9c2d9112fe667221c199405d5336af5a23a90ec9b97a76546339e5618b42a7d3.

  • Registration is not evidence that a study succeeded, that results were published, or that a use is approved.
  • Other registries, unregistered studies and additional aliases remain outside this query.

Showing 25 of 30 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

  1. ClinicalTrials.gov NCT06596135 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
  2. ClinicalTrials.gov NCT05812183 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
  3. ClinicalTrials.gov NCT03262610 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
  4. ClinicalTrials.gov NCT03479437 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
  5. ClinicalTrials.gov NCT03651765 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
  6. ClinicalTrials.gov NCT05046132 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
  7. ClinicalTrials.gov NCT03287960 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
  8. ClinicalTrials.gov NCT02849977 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
  9. ClinicalTrials.gov NCT06772597 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
  10. ClinicalTrials.gov NCT02041195 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
  11. ClinicalTrials.gov NCT03746522 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
  12. ClinicalTrials.gov NCT04963231 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
  13. ClinicalTrials.gov NCT05194124 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
  14. ClinicalTrials.gov NCT04966741 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
  15. ClinicalTrials.gov NCT05183802 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
  16. ClinicalTrials.gov NCT02507492 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
  17. ClinicalTrials.gov NCT02431442 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
  18. ClinicalTrials.gov NCT03621007 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
  19. ClinicalTrials.gov NCT05093634 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
  20. ClinicalTrials.gov NCT06760546 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
  21. ClinicalTrials.gov NCT03013543 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
  22. ClinicalTrials.gov NCT01749137 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
  23. ClinicalTrials.gov NCT07674290 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
  24. ClinicalTrials.gov NCT04348175 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
  25. ClinicalTrials.gov NCT01867437 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
Explore status sources, recent additions, and coverage gaps

Living status brief

What is the current status of Setmelanotide?

FDA-approved as Imcivree for specific rare causes of obesity. A randomized, placebo-controlled trial in 142 people with acquired hypothalamic obesity and smaller open-label trials in genetic forms of obesity are described in the label. The label states that it is not indicated for general obesity.↗↗

The cited status sources were checked through July 22, 2026. This answer changes only through the profile’s visible version and correction history.

Evidence present

What records are connected here?

Evidence lanes
3
Source years
7
Drugs@FDA applications
1

These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.

Coverage gaps

What remains unknown or unsupported?

PeptideScanner currently has no selected safety records connected to this profile. That is a collection gap, not evidence that no such records exist.

PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.

Explore the Evidence Map and record counts

Evidence Map v1

What kinds of records connect to Setmelanotide?

Compare collection coverage →

This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.

70Selected dated records
71Connected citations
7Populated source years2020–2026
3/4Record lanes present

Registered human studies

Trial composition

6 of 14 selected trial records include at least one phase value; 6 of 14 include a status value in the retained structured contract.

156 public history versions connect to 12 of these trial records across 11 submitted years. Open the record-history collection →

6 exact source-declared trial-publication links connect selected NCT and PMID records. Open the exact graph →

PhasesPhase 3 3Phase 2 2Phase 4 1
Status at observationCompleted 2Recruiting 2Active, not recruiting 1Enrolling by invitation 1

A phase value is unavailable here for 8 selected records; this is not counted as “no phase.”

A status value is unavailable here for 8 selected records; this is not counted as a trial status.

PubMed bibliography

Publication composition

18 of 41 selected PubMed records include attributed title, venue, publication date, and publication-type fields.

Publication typesJournal Article 15Comment 5Letter 3Research Support, Non-U.S. Gov't 3Review 3Clinical Trial 1Clinical Trial, Phase II 1Multicenter Study 1

Bibliography fields unavailable here for 23 selected records; the records remain visible as metadata observations.

Regulatory and publication surfaces

What is structurally connected?

Drugs@FDA applications
1
FDA Federal Register documents
4
DailyMed SPL versions
10
Canonical profile
Published
Profile structured data
Published
Linked dated records
70

Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.

Profile publication history and record counts
Trial–publication links · 6

Exact identifier graph

6 trial-publication links for Setmelanotide

Open the full graph →

These links come only from structured NCT and PMID identifiers declared by PubMed or ClinicalTrials.gov. They do not summarize the publications or establish findings.

Source records by collection · 70 dated records

Research hub

Explore the Setmelanotide evidence record

Open all 70 records →
70Dated records
3Evidence types
70Cited public sources
7Source years

Change ledger

Recently changed for Setmelanotide

Open all 75 events →

PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.

Record updated

Patient and caregiver experiences with a patient-support program for setmelanotide treatment of patients with Bardet-Biedl syndrome.

PubMed revised the bibliographic metadata of PMID 40484968, with a metadata revision date of 2026-10-14. This version reports that observation; the earlier retained observation remains available as version 1.

PeptideScanner change date
November 16, 2026
Cited source date
October 14, 2026
Evidence lane
Literature metadata
Record updated

ClinicalTrials.gov record NCT05093634

ClinicalTrials.gov posted a newer version of NCT05093634, with a registry update date of 2026-11-12. This version reports that observation; the earlier retained observation remains available as version 1.

PeptideScanner change date
November 15, 2026
Cited source date
November 12, 2026
Evidence lane
Clinical trials
Record updated

ClinicalTrials.gov record NCT06772597

ClinicalTrials.gov posted a newer version of NCT06772597, with a registry update date of 2026-11-13. This version reports that observation; the earlier retained observation remains available as version 1.

PeptideScanner change date
November 15, 2026
Cited source date
November 13, 2026
Evidence lane
Clinical trials

Official-source collections

Source records for Setmelanotide

Open the full research atlas →
PubMed41

18 with attributed title, venue, publication-date, and type metadata.

  1. Early nutrition impacts later setmelanotide treatment of obesity in mice.JCI insight · 2026 11 09
  2. Setmelanotide for the Treatment of Acquired Hypothalamic Obesity. Reply.The New England journal of medicine · 2026 Oct 15
  3. Setmelanotide for the Treatment of Acquired Hypothalamic Obesity.The New England journal of medicine · 2026 Oct 15
Explore all selected literature →
ClinicalTrials.gov14

156 public history versions across these dated registry records; status labels apply only to each cited observation.

  1. NCT06772597Registry update November 13, 2026 · current at observation
  2. NCT05093634Registry update November 12, 2026 · completed at observation
  3. NCT07496463Registry update July 23, 2026 · current at observation
Explore all selected trial records →Explore all public record history →
DailyMed SPL history10

Version metadata and exact historical ZIP receipts for the reviewed label family, without reproducing or interpreting label text.

  1. SPL version 14Published 2026-04-02 · ZIP SHA-256 3a9024abc434…
  2. SPL version 13Published 2025-12-22 · ZIP SHA-256 bd3173681d44…
  3. SPL version 12Published 2025-09-05 · ZIP SHA-256 1b6551ccd1b9…
  4. SPL version 9Published 2025-05-23 · ZIP SHA-256 820af867ea8d…
  5. SPL version 8Published 2025-05-19 · ZIP SHA-256 0c923dbdc6d2…
Explore all DailyMed label versions →

Evidence types

Coverage by source year

Selected records span November 25, 2020 to November 13, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.

Continue exploring

Profiles with overlapping source-year coverage

Open the research atlas →

These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.

Organizations and trial records named in cited sources

Organizations named in cited records

  • U.S. National Library of Medicine1
  • U.S. Food and Drug Administration2
Dated updates connected to this profile · 70

Updates connected to this profile

Open the full cross-source timeline →
  1. Clinical trials

    ClinicalTrials.gov record NCT06772597↗

    PeptideScanner retained ClinicalTrials.gov record NCT06772597 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-13, and PeptideScanner's reviewed identity mapping was setmelanotide.↗

  2. Clinical trials

    ClinicalTrials.gov record NCT05093634↗

    PeptideScanner retained ClinicalTrials.gov record NCT05093634 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was setmelanotide.↗

  3. Literature metadata

    Early nutrition impacts later setmelanotide treatment of obesity in mice.↗

    PubMed lists PMID 43001579 in JCI insight as Journal Article, with publication-date metadata of 2026-11-09 (day precision). PeptideScanner associated the retained record with the identity slug setmelanotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  4. Literature metadata

    Setmelanotide for the Treatment of Acquired Hypothalamic Obesity.↗

    PubMed lists PMID 42874119 in The New England journal of medicine as Letter, Comment, with publication-date metadata of 2026-10-15 (day precision). PeptideScanner associated the retained record with the identity slug setmelanotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  5. Literature metadata

    Setmelanotide for the Treatment of Acquired Hypothalamic Obesity.↗

    PubMed lists PMID 42874120 in The New England journal of medicine as Letter, Comment, with publication-date metadata of 2026-10-15 (day precision). PeptideScanner associated the retained record with the identity slug setmelanotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  6. Literature metadata

    Setmelanotide for the Treatment of Acquired Hypothalamic Obesity. Reply.↗

    PubMed lists PMID 42874121 in The New England journal of medicine as Letter, Comment, with publication-date metadata of 2026-10-15 (day precision). PeptideScanner associated the retained record with the identity slug setmelanotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  7. Literature metadata

    Patient and caregiver experiences with a patient-support program for setmelanotide treatment of patients with Bardet-Biedl syndrome.↗

    PubMed lists PMID 40484968 in Orphanet journal of rare diseases as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2025-06-08 (day precision). PeptideScanner associated the retained record with the identity slug setmelanotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  8. Literature metadata

    PubMed record PMID 42498078↗

    PeptideScanner retained PubMed bibliographic metadata for PMID 42498078 at 2026-08-10T10:49:10.787Z. PubMed recorded a metadata revision date of 2026-08-01 and an Entrez history date of 2026-07-24. PeptideScanner associated this retained record with the identity slug setmelanotide. These dates describe PubMed metadata history, not the article's original publication date.↗

  9. Literature metadata

    PubMed record PMID 42538728↗

    PeptideScanner retained PubMed bibliographic metadata for PMID 42538728 at 2026-08-10T10:49:12.953Z. PubMed recorded a metadata revision date of 2026-08-01 and an Entrez history date of 2026-08-01. PeptideScanner associated this retained record with the identity slug setmelanotide. These dates describe PubMed metadata history, not the article's original publication date.↗

  10. Literature metadata

    PubMed record PMID 42008191↗

    PeptideScanner retained PubMed bibliographic metadata for PMID 42008191 at 2026-08-10T10:49:08.851Z. PubMed recorded a metadata revision date of 2026-07-30 and an Entrez history date of 2026-04-20. PeptideScanner associated this retained record with the identity slug setmelanotide. These dates describe PubMed metadata history, not the article's original publication date.↗

  11. Literature metadata

    PubMed record PMID 42528856↗

    PeptideScanner retained PubMed bibliographic metadata for PMID 42528856 at 2026-08-10T10:49:12.911Z. PubMed recorded a metadata revision date of 2026-07-30 and an Entrez history date of 2026-07-30. PeptideScanner associated this retained record with the identity slug setmelanotide. These dates describe PubMed metadata history, not the article's original publication date.↗

  12. Literature metadata

    PubMed record PMID 41894554↗

    PeptideScanner retained PubMed bibliographic metadata for PMID 41894554 at 2026-08-10T18:13:44.905Z. PubMed recorded a metadata revision date of 2026-07-26 and an Entrez history date of 2026-03-27. PeptideScanner associated this retained record with the identity slug setmelanotide. These dates describe PubMed metadata history, not the article's original publication date.↗

Citations

Sources

Coverage and sources →

Numbered markers in the text point here. Each link opens the original public record.

  1. 1
    IMCIVREE (setmelanotide) solution · SPL version 14 · published 2026-04-02 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked July 22, 2026

  2. 2
    Drugs@FDA application NDA213793 · original submission status AP · 2020-11-25 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026